<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406132</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK03</org_study_id>
    <nct_id>NCT01406132</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate pharmacokinetics, in particular the routes of
      excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled
      ASP015K.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be admitted to the clinical research unit and confined for a minimum
      of 8 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment through radiographic and high performance liquid chromatography (HPLC) analysis of blood, urine and feces samples</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics of ASP015K</condition>
  <arm_group>
    <arm_group_label>ASP015K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP015K</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a body weight of at least 45 kg and a body mass index (BMI) between 18
             and 32 kg/m2, inclusive

          -  The subject has been a non-smoker for at least 3 months prior to check-in

          -  The subject agrees to sexual abstinence, is surgically sterile (with documentation
             provided by a healthcare professional), or is using a medically acceptable method to
             prevent pregnancy during the study period

          -  The subject's clinical laboratory test results are within normal limits

          -  The subject is medically healthy, with no clinically significant medical history or
             abnormalities

        Exclusion Criteria:

          -  The subject has a history of any clinically significant gastrointestinal, cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy
             excluding non-melanoma skin cancer

          -  The subject has a history of malabsorption syndrome or previous gastrointestinal
             surgery that could affect drug absorption or metabolism

          -  The subject has a recent history of irregular defecation, such as constipation or
             diarrhea

          -  The subject has a history of drug or alcohol abuse, or a positive urine screen for
             alcohol or drugs of abuse/illegal drugs

          -  The subject has had treatment with prescription drugs or complementary and alternative
             medicines (CAM) within 14 days prior to study drug administration, or over the counter
             (OTC) medication within past week

          -  The subject has/had a symptomatic, viral, bacterial (including upper respiratory
             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in

          -  The subject is known positive for human immunodeficiency virus (HIV) antibody

          -  The subject has a positive test for hepatitis C antibody, or positive test for
             hepatitis B antigen (HBsAg)

          -  The subject has positive tuberculosis (TB) or Quantiferon Gold test

          -  The subject has received an experimental agent within 30 days or five half-lives,
             whichever is longer, prior to study drug administration

          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or
             more, or received a transfusion of any blood or blood products within 60 days or
             donated plasma within 7 days prior to clinic admission

          -  The subject has had exposure to significant radiation (eg, serial x-ray or computed
             tomography scans, barium meal, current employment in a job requiring radiation
             exposure monitoring) within 12 months prior to check-in

          -  The subject has participated in a radio-labeled-study within the last 6 months,
             participated in more than one other radio-labeled study within the past 12 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CCRU)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

